Abstract:Purpose: Oncogenic driver mutations in either KRAS or EGFR are present in up to 40-50% of NSCLC, share activation of the MAPK/ERK pathway and may be amenable to combination therapy to prevent negative feedback activation. In a phase I/IB trial, we tested the oral MEK 1/2 inhibitor, binimetinib, with EGFR-TKI, erlotinib, to establish MTD and evaluate safety of combination in patients with NSCLC harboring KRAS or EGFR mutations. Patients and Methods: Patients with advanced/metastatic NSCLC with at least 1 prior line of treatment (unless with activating EGFR mutation which could be treatment-naïve) were enrolled. The Phase I dose-escalation portion used a 3+3 design to determine the RP2D. Phase IB expansion enrolled patients with either KRAS- or EGFR-mutant NSCLC using the RP2D determined in Phase I. The primary objective was to evaluate the safety of binimetinib plus erlotinib in both phases. Tumor assessments were performed every two 28-day cycles. Blood samples were collected for pharmacokinetic analyses and tumor sampling was assessed to explore the biomarkers that could predict response or resistance to the binimetinib and erlotinib combination. Statistical analyses were performed via SAS 9.4. Results: 43 patients were enrolled (dose-escalation = 23; expansion = 20). Median age: 67 years (range 32-80); Females: 20 (47%); ECOG performance status 1: 37 (86%); never/former/current smokers: 10/27/6 (23%/63%/14%); and median 2 prior lines of treatment (range 0 - 5). 17 patients (40%) harbored EGFR mutation (10 exon 19 del, 6 L858R substitution, 1 G719D) and 22 (51%) harbored KRAS mutation (10 G12C, 11 other). The RP2D was erlotinib 100 mg QD continuously and binimetinib 15 mg BID x 5 days/week. The most common AEs across all dose levels included diarrhea (69.8%), rash (44.2%), fatigue (32.6%), and nausea (32.6%). Adverse events were primarily grade 1 or 2. Among the 43 patients enrolled, 9 (21%) achieved partial response (PR), 10 (23%) achieved stable disease (SD), and 9 (21%) had progressive disease. The remaining 15 patients (36%) were not evaluable for response. Among KRAS-mutant patients, 1 (5%) had confirmed PR (with G12D) and 8 (36%) achieved SD. Among EGFR-mutant patients, 9 were TKI-naïve including 8 PR (89%); 8 were TKI-pretreated with no PR and 1 (13%) SD. Median OS overall was 17.0 months (95% CI: 12.0, N.E.) and median PFS was 5.5 months (95% CI: 3.6, 22.2). Pharmacokinetics of binimetinib were comparable to historical data with no evidence of significant drug interaction with erlotinib. Correlative analyses are underway to assess on target effects, outcomes by mutation subtype and resistance mechanism. Conclusion: Binimetinib plus erlotinib demonstrated a manageable safety profile and modest efficacy including one objective response in a patient with KRAS mutation. With novel small molecule inhibitors of RAS and selective EGFR and other MAPK pathway inhibitors in development, these results support that such combination targeted approaches may hold clinical utility. Citation Format: Andreas N. Saltos, Benjamin C. Creelan, Tawee Tanvetyanon, Alberto A. Chiappori, Scott J. Antonia, Michael R. Shafique, Milijana Ugrenovic-Petrovic, Samer Sansil, Anthony M. Neuger, Jongphil Kim, Eric Haura, Jhanelle Gray. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr CT515.

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E

Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

STOPTRAFFIC-1: A Phase I/II Trial of SX-682 in Combination with Nivolumab for Refractory RAS-mutated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (Mcrc).

Abstract CT515: A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation

A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

A Phase II Trial of Sitravatinib Plus Nivolumab after Progression on Prior Immune Checkpoint Inhibitor (ICI) in Patients with Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc).

Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

A Phase Iii Randomized Open Label Study Comparing Bempegaldesleukin (Nktr-214) Plus Nivolumab To Sunitinib Or Cabozantinib (Investigator'S Choice) In Patients With Previously Untreated Advanced Renal Cell Carcinoma.

Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair–Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D

Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6

A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC

A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).